top of page
owenhaskins

ASMBS appoints Diane Enos as new Executive Director

The American Society for Metabolic and Bariatric Surgery (ASMBS), the nation’s largest professional organisation of bariatric and metabolic surgeons and integrated health professionals, has named healthcare association veteran Diane Enos to serve as its new Executive Director.

Diane Enos

“I’m looking forward to working with our team and our members to grow the specialty and increase the role of metabolic and bariatric surgery in the treatment of obesity,” said Enos. “Obesity remains the public health issue of our time and we owe it to our patients to remove barriers to treatment and help them navigate the new treatment landscape so they can turn their concerns about the dangers of the disease into action.”


Before joining ASMBS, Enos, a registered dietitian and certified association executive with a master’s degree in public health from the University of Texas Health Science Center in Houston, was Chief Learning Officer of the Academy of Nutrition and Dietetics, the country’s largest organisation of food and nutrition professionals. Enos was with the group for more than 20 years in various leadership positions and remains a Fellow of the Academy (FAND). Previously, Enos was Manager of National Consumer Communications for the USA Rice Federation.


Enos becomes only the second executive director in the organization’s history succeeding Georgeann Mallory who retired from the role in 2021. Kristie Kaufman, who has been with ASMBS for more than 20 years, served as interim executive director between 2021 and 2023, and has been promoted to Vice President of Operations.


“Diane brings a wealth of experience, a track record of success and new insights that will help strengthen our organization at a time of rising obesity rates and new thinking on how best to treat the disease and when,” said Dr Marina Kurian, President, ASMBS. “We expect increased utilisation of metabolic and bariatric surgery and growing demand for the new class of obesity drugs to usher in a new era of obesity treatment that could transform public health.”

Comentários


bottom of page